Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma

Norihito Soga, Koichiro Yamakado, Hideo Gohara, Haruyuki Takaki, Takao Hiraki, Tomomi Yamada, Kiminobu Arima, Kan Takeda, Susumu Kanazawa, Yoshiki Sugimura

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)


Objective: To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence-free survival in the curative ablation group. RESULTS There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P < 0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow-up of 25 months. The recurrence-free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications. CONCLUSION Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.

Original languageEnglish
Pages (from-to)790-794
Number of pages5
JournalBJU International
Issue number6
Publication statusPublished - Sep 2009


  • Lung metastasis
  • Percutaneous radiofrequency ablation
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma'. Together they form a unique fingerprint.

Cite this